Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 150 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Antiandrogen Clear all
Completed Phase 3 Interventional Results available

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

NCT00004054
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, estramustine phosphate sodium, etoposide, flutamide, paclitaxel, Luteinizing hormone releasing hormone [LHRH] agonist, Radiation therapy, warfarin
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Concord, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 17, 2026, 11:10 AM EDT
Completed Phase 3 Interventional Results available

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

NCT02799602
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer
Interventions
BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy), Docetaxel, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
58
States / cities
Chandler, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 17, 2026, 11:10 AM EDT
Terminated Phase 1 Interventional

Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer

NCT02349139
View directory record Official record
Conditions
Cancer of the Prostate, Neoplasms, Prostate, Prostate Cancer, Prostatic Cancer, Neoplasms, Prostatic, Prostate Neoplasms, Castration-resistant
Interventions
ASN001: Escalating dose Part A
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
6
States / cities
Los Angeles, California • Detroit, Michigan • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 17, 2026, 11:10 AM EDT
Recruiting Phase 2 Interventional

Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

NCT03541928
View directory record Official record
Conditions
High-risk Prostate Cancer, Prostate Cancer
Interventions
HSV-Tk, Valacyclovir, Bicalutamide, Leuprolide Acetate, Brachytherapy, External beam radiotherapy, Radical prostatectomy
Drug · Radiation · Procedure
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 17, 2026, 11:10 AM EDT
Completed Phase 2 Interventional

Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer

NCT06312670
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer, Prostate Adenocarcinoma
Interventions
EPI-7386, Enzalutamide, Androgen Deprivation Therapy (ADT)
Drug
Lead sponsor
Pedro Barata, MD, MSc
Other
Eligibility
19 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 17, 2026, 11:10 AM EDT
Terminated Phase 2 Interventional Results available

Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer

NCT04298983
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abemaciclib 150 MG by mouth twice daily, Androgen deprivation therapy (ADT), Radiation Therapy
Drug · Radiation
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 17, 2026, 11:10 AM EDT
Completed Phase 1 Interventional

PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer

NCT02472275
View directory record Official record
Conditions
Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
Interventions
Antiandrogen Therapy, Laboratory Biomarker Analysis, Multitargeted Tyrosine Kinase Inhibitor PLX3397, Radiation Therapy
Drug · Other · Radiation
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
3
States / cities
Detroit, Michigan • Petoskey, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 17, 2026, 11:10 AM EDT
Completed Phase 2 Interventional Results available

The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

NCT03899467
View directory record Official record
Conditions
Metastatic Castrate Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
GT0918
Drug
Lead sponsor
Suzhou Kintor Pharmaceutical Inc,
Industry
Eligibility
18 Years and older · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Athens, Georgia • Louisville, Kentucky • Towson, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Oct 17, 2026, 11:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Radiation and Androgen Ablation for Prostate Cancer

NCT01517451
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
Radiation Therapy, Androgen Deprivation Therapy (ADT)
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 17, 2026, 11:10 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

NCT03070886
View directory record Official record
Conditions
Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Interventions
Bicalutamide, Degarelix, Docetaxel, External Beam Radiation Therapy, Flutamide, Goserelin, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide, Leuprolide Acetate, Nilutamide
Drug · Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
311
States / cities
Mobile, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 254 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 17, 2026, 11:10 AM EDT
Completed No phase listed Observational

Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy

NCT00002924
View directory record Official record
Conditions
Prostate Cancer
Interventions
mutation analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Male only
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
49
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 17, 2026, 11:10 AM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

NCT00002597
View directory record Official record
Conditions
Prostate Cancer
Interventions
flutamide, Zoladex, Lupron, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
2,028 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2018
U.S. locations
222
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 173 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 17, 2026, 11:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Androgen Deprivation Therapy on Cardiovascular Function in Prostate Cancer

NCT03275181
View directory record Official record
Conditions
Prostate Cancer
Interventions
Transthoracic Echocardiography, Arterial blood pressure, Submaximal Exercise
Diagnostic Test
Lead sponsor
Kansas State University
Other
Eligibility
21 Years to 80 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Manhattan, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 17, 2026, 11:10 AM EDT
Completed Early Phase 1 Interventional

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash

NCT03471364
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Ketoconazole, Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
6
States / cities
Danville, Illinois • Urbana, Illinois • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 17, 2026, 11:10 AM EDT
Active, not recruiting Phase 2 Interventional

Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer

NCT04267887
View directory record Official record
Conditions
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Antiandrogen Therapy, Apalutamide, Prednisone, Computed Tomography, Bone Scan, Biospecimen Collection, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 17, 2026, 11:10 AM EDT
Terminated Phase 2 Interventional

A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer

NCT00006371
View directory record Official record
Conditions
Prostate Cancer
Interventions
aminoglutethimide, ketoconazole, therapeutic hydrocortisone
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Oct 17, 2026, 11:10 AM EDT
Completed Phase 2 Interventional Results available

Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer

NCT00283803
View directory record Official record
Conditions
Prostate Cancer
Interventions
Exisulind, luteinizing hormone-releasing hormone (LHRH) agonist, Antiandrogen
Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 17, 2026, 11:10 AM EDT
Completed No phase listed Observational

Prospective Study of Insulin Resistance and Cardiovascular Disease Risk During Androgen Deprivation Therapy for Prostate Cancer

NCT00455624
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen deprivation therapy
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 17, 2026, 11:10 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC

NCT06222593
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Bicalutamide in combination with Sunitinib
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 17, 2026, 11:10 AM EDT
Recruiting Phase 2 Interventional

PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

NCT06392295
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Hormone Sensitive Prostate Cancer
Interventions
Para Aortic Radiation Therapy: Photon Therapy, Para Aortic Radiation Therapy: Proton Therapy, Androgen Deprivation Therapy, Androgen Receptor Signaling Inhibitor
Radiation · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 17, 2026, 11:10 AM EDT
Not listed Phase 3 Interventional Results available

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

NCT00567580
View directory record Official record
Conditions
Prostate Cancer
Interventions
PBRT, PLNRT, AA, LHRH agonist
Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
1,792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
444
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 316 more
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 17, 2026, 11:10 AM EDT
Completed Phase 3 Interventional Results available

Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

NCT00309985
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer
Interventions
androgen-deprivation therapy, docetaxel
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Male only
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2025
U.S. locations
343
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 243 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 17, 2026, 11:10 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

HDR Brachytherapy, EBRT and STAD for the Treatment of Prostate Cancer

NCT03553602
View directory record Official record
Conditions
Prostate Cancer - Recurrent
Interventions
HDR Brachytherapy + EBRT + STAD
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 17, 2026, 11:10 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris

NCT02682264
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CB-03-01 cream, 1%
Drug
Lead sponsor
Cassiopea SpA
Industry
Eligibility
9 Years and older
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
39
States / cities
Fort Smith, Arkansas • Little Rock, Arkansas • Sacramento, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 17, 2026, 11:10 AM EDT